Labcorp Announces 2025 Second Quarter Results

Original from: Labcorp

Raises Full-Year Guidance

· Financial results from Operations for second quarter 2025 versus second quarter 2024:

 - Revenue:  $3.53 billion  versus  $3.22 billion

 - Diluted EPS:  $2.84  versus  $2.43

 - Adjusted EPS:  $4.35  versus  $3.94

· Raised Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance:

 - Revenue guidance narrowed to 7.5% to 8.6%; midpoint raised by 70 basis points

 - Adjusted EPS range narrowed to  $16.05  to  $16.50 ; midpoint raised by  $0.23

 - Free Cash Flow range of  $1.13 billion  to  $1.28 billion ; midpoint raised by  $25 million

· Broadened our partnerships with hospitals, health systems and regional/local labs and enhanced access to comprehensive testing and laboratory services

· Introduced several new tests in high-growth specialty areas including oncology

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the second quarter ended June 30, 2025 and raised full-year guidance.

"Labcorp had a very strong second quarter, delivering double-digit topline growth, while expanding margins across both segments," said Adam Schechter, chairman and CEO of Labcorp. "We brought innovative tests to market, and applied our leadership in science and technology to drive growth, enhance the customer experience and improve our operations.  We remain committed to delivering sustained value to our customers, employees and shareholders as we execute on our long-term strategy. Based upon our performance in the first half and our momentum going into the second half of the year, we're raising our guidance."

In the second quarter, Labcorp advanced its position as a partner of choice for hospitals, health systems and regional/local laboratories:

· Announced an agreement to acquire select assets of Incyte Diagnostics' clinical and anatomic pathology testing businesses in the Pacific Northwest.

· Continued to progress the acquisition of select oncology and clinical testing assets from BioReference Health.

· Subsequent to quarter end, Labcorp announced an agreement to acquire select assets of the outreach business from Community Health Systems across 13 states.

Labcorp also continued to incorporate the power of science, innovation and technology across the organization during or subsequent to the quarter:

· Expanded its oncology portfolio with key launches including Labcorp® Plasma Detect™, a liquid biopsy test that assesses colon cancer recurrence risk and PGDx elio® plasma focus™ Dx, the first-and-only FDA-authorized pan-solid tumor liquid biopsy test for targeted treatment guidance.

· Continued to advance its leading position in Alzheimer's disease, and plans in the coming weeks to offer Fujirebio FDA-cleared biomarker test that aids in diagnosing the disease.

· Expanded its consumer offerings by launching several consumer-initiated tests through Labcorp OnDemand, including tests that measure an individual's cortisol and leptin levels, and introducing a new and improved Ovia app, providing women with a single platform to support their health journey.

· Introduced Labcorp Whole Health Solutions for functional medicine, integrative medicine and primary care practices. The solution offers specialized test panels and a test menu of more than 1,000 scientifically backed biomarkers.

· Added digital pathology capabilities in Central Labs, including advanced image scanning to preserve critical sample data and AI-powered solutions to provide analysis on large datasets instantly.

On July 10, 2025, the company announced a quarterly cash dividend of $0.72 per share of common stock, payable on September 11, 2025, to stockholders of record at the close of business on August 28, 2025. In the quarter, Labcorp repurchased $200 million of common stock.

Additionally, Labcorp raised 2025 guidance for enterprise revenue, adjusted EPS and free cash flow primarily driven by currency, as well as the underlying strength of its businesses.

Source: Labcorp Announces 2025 Second Quarter Results